Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, has announced the grant of 21,000 restricted stock units to three new employees. The grants were approved by the company's Compensation Committee and issued under the 2022 Inducement Plan.
The stock units, granted on August 1, 2025, will vest over a four-year period, with 25% vesting annually on each anniversary of the vesting commencement date. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Arcutis Biotherapeutics (Nasdaq: ARQT), azienda biofarmaceutica in fase commerciale specializzata in immunodermatologia, ha annunciato l'assegnazione di 21.000 unità azionarie vincolate a tre nuovi dipendenti. Le assegnazioni sono state approvate dal Comitato per la retribuzione e effettuate ai sensi del Piano di incentivazione 2022.
Le unità azionarie, concesse il 1 agosto 2025, matureranno nell'arco di quattro anni, con il 25% che matura ogni anno in corrispondenza dell'anniversario della data di inizio della maturazione. Le assegnazioni sono state effettuate conformemente alla Regola di quotazione Nasdaq 5635(c)(4) come incentivo all'assunzione.
Arcutis Biotherapeutics (Nasdaq: ARQT), una compañía biofarmacéutica en etapa comercial especializada en inmunodermatología, anunció la concesión de 21.000 unidades de acciones restringidas a tres nuevos empleados. Las concesiones fueron aprobadas por el Comité de Compensación de la compañía y otorgadas en virtud del Plan de Incentivos 2022.
Las unidades, otorgadas el 1 de agosto de 2025, se consolidarán a lo largo de cuatro años, con un 25% que se consolida cada año en el aniversario de la fecha de inicio del periodo de consolidación. Las concesiones se realizaron de conformidad con la Regla de Cotización de Nasdaq 5635(c)(4) como incentivo por contratación.
Arcutis Biotherapeutics (Nasdaq: ARQT)는 면역피부과를 전문으로 하는 상업화 단계의 바이오제약사로, 세 명의 신규 직원에게 21,000 제한 주식 단위(Restricted Stock Units)를 부여했다고 발표했습니다. 이 부여는 회사의 보상위원회에서 승인되었으며 2022 유인(Inducement) 플랜에 따라 이루어졌습니다.
해당 주식 단위는 2025년 8월 1일에 부여되었으며 4년 동안 점진적으로 권리확보(베스팅)되며, 권리확정 시작일의 매 기념일마다 25%씩 연간 베스팅됩니다. 이 부여는 채용 유인으로서 나스닥 상장 규정 5635(c)(4)에 따라 이루어졌습니다.
Arcutis Biotherapeutics (Nasdaq: ARQT), une société biopharmaceutique en phase commerciale spécialisée en immuno-dermatologie, a annoncé l'attribution de 21 000 unités d'actions restreintes à trois nouveaux employés. Les attributions ont été approuvées par le comité de rémunération de la société et émises en vertu du plan d'incitation 2022.
Les unités, attribuées le 1er août 2025, seront acquises sur une période de quatre ans, avec 25 % qui s'acquiert chaque année à l'anniversaire du début de la période d'acquisition. Les attributions ont été effectuées conformément à la règle de cotation Nasdaq 5635(c)(4) en tant qu'incitation à l'embauche.
Arcutis Biotherapeutics (Nasdaq: ARQT), ein im kommerziellen Stadium befindliches biopharmazeutisches Unternehmen mit Schwerpunkt Immundermatologie, hat die Gewährung von 21.000 Restricted Stock Units an drei neue Mitarbeiter bekanntgegeben. Die Zuteilungen wurden vom Vergütungsausschuss des Unternehmens genehmigt und unter dem Inducement-Plan 2022 gewährt.
Die am 1. August 2025 gewährten Einheiten werden über einen Zeitraum von vier Jahren vesten, wobei jeweils 25 % jährlich am Jahrestag des Beginns der Vesting-Periode vesten. Die Zuteilungen erfolgten gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Einstellungsanreiz.
- None.
- None.
WESTLAKE VILLAGE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 21,000 restricted stock units of Arcutis’ common stock to three newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of August 1, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to the employee being continuously employed by Arcutis as of such vesting dates.
Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform coupled with our dermatology expertise allows us to invent differentiated therapies against biologically validated targets, and has produced a robust pipeline with multiple follow-on clinical programs for a range of inflammatory dermatological conditions including atopic dermatitis and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com
FAQ
What stock compensation did Arcutis Biotherapeutics (ARQT) grant to new employees in August 2025?
What is the vesting schedule for Arcutis Biotherapeutics' (ARQT) August 2025 restricted stock units?
Under which plan were the Arcutis Biotherapeutics (ARQT) inducement grants issued?
How many new employees received Arcutis Biotherapeutics (ARQT) restricted stock units in August 2025?
